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Abstract
Background: Previous studies indicate that natural bispecific antibodies can be readily produced in vivo when the body is
simultaneously stimulated with 2 distinct antigens. Patients with rheumatoid arthritis (RA) usually exhibit persistent immune
responses to various autoantigens, raising the possibility that natural bispecific antibodies against 2 distinct autoantigens
might exist.
Methodology/Principal Findings: We identified the presence of natural bispecific antibodies against cyclic citrullinated
peptide (CCP) and immunoglobulin G (IgG) in RA patients’ sera by means of a double-antigen sandwich enzyme-linked
immunosorbent assay (ELISA). The spontaneous emergence of bispecific antibodies was confirmed by mixing different
proportions of 1 anti-CCP-positive serum and 1 rheumatoid factor (RF)-positive serum in vitro. Among the tested samples,
positive correlations were found between the presence of bispecific antibodies and both IgG4 anti-CCP antibodies and IgG4
RF (r=0.507, p,0.001 and r=0.249, p=0.044, respectively), suggesting that the IgG4 subclass is associated with this
phenomenon. Furthermore, bispecific antibodies were selectively generated when several anti-CCP- and RF-positive sera
were mixed pairwise, indicating that factors other than the monospecific antibody titers may also contribute to the
production of the natural bispecific antibodies.
Conclusions/Significance: We successfully identified the presence of natural bispecific antibodies. Our results suggest that
these antibodies originate from anti-CCP and RF in the sera of RA patients. The natural occurrence of bispecific antibodies in
human diseases may provide new insights for a better understanding of the diseases. Further investigations are needed to
elucidate their precise generation mechanisms and explore their clinical significance in disease development and
progression in a larger study population.
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Introduction
We have previously reported the production of natural
bispecific antibodies in rabbits that were simultaneously immu-
nized with 2 unrelated antigens [1]. Rabbits immunized with an
antigen mixture containing 2 conjugated carrier-hapten(s) (BSA-
digoxin and KLH-DNP) produce as many as 6 types of natural
bispecific antibodies against antigen pairs that combine randomly
[1]. Thus, 2 distinct antigens’ simultaneous stimulation is critical
for the natural occurrence of bispecific antibodies in vivo. Another
research group working on natural bispecific antibodies originat-
ing from half-molecule exchanges of IgG4 obtained similar results.
Schuurman et al. [2] found that a class of natural bispecific
antibodies could be obtained from allergic patients receiving
therapeutic injections with 2 different allergens during specific
immunotherapy. The mechanism for the production of natural
bispecific antibodies is indicated by exchanges of IgG4 half-
molecule(s) (a heavy chain and an attached light chain) between 2
antibody molecules [3–5]. Taken together, the simultaneous
stimulation with 2 distinct antigens is the precondition for the
production of natural bispecific antibodies in vivo. Two mono-
specific antibody populations that are subsequently generated and
secreted by the plasma cells interact with each other via a half-
molecule exchange, resulting in a new group of antibody
molecules exhibiting 2 distinct antigen-binding sites.
Most autoimmune diseases are characterized by the production
of various autoantibodies against autoantigens. Rheumatoid
arthritis (RA) is a common systemic autoimmune disease of
unknown etiology that is characterized by chronically inflamed
synovial joints and subsequent destruction of cartilage and bones.
The inflammatory synovium is a good place for accommodating
targets for a broad range of autoantibodies. The extended disease
duration accompanied by persistent immune responses to
autoantigens is a situation that is quite similar to our established
animal model for natural bispecific antibody production. The
main difference is that a spontaneous autoimmune response
underlies the disease situation, while active immunization is the
driver in the animal model. In another words, RA theoretically
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tion, which leads us to speculate that some natural bispecific
antibody against 2 distinct autoantigens might exist. Rheumatoid
factors (RF) and anti-cyclic citrullinated peptide antibodies (anti-
CCP) are frequently found in the sera and synovial fluids of most
RA patients and are believed to be pivotal markers of the disease
[6]. Furthermore, a positive correlation between anti-CCP and RF
is reported in several studies [7–9]. On the other hand, studies on
subclass distribution indicate that IgG4 is conspicuously elevated
in IgG RF and IgG anti-CCP, only secondarily to IgG1 [10–12].
Thus, they are more likely to fit the conditions for natural
bispecific antibody production such as simultaneous autoantigen
stimulation and post-secretion encounters for half-molecule
exchanges.
In the present study, we attempt to identify a type of natural
bispecific antibodies originating from anti-CCP and RF in RA.
Materials and Methods
Patients and controls
Serum samples were obtained from 66 patients who fulfilled the
American College of Rheumatology criteria for RA [13]. For
comparison, 112 control subjects were tested as well; 62 had the
following other autoimmune diseases: 37 with systemic lupus
erythematosus (SLE), 16 with primary Sjo ¨gren syndrome (pSS),
and 9 with scleroderma. Fifty healthy subjects were also included.
Serum samples were stored at 280uC until analysis. The RA
group consisted of 50 women and 16 men. The mean (SD) age of
this group was 48.6 (13.9) years (range: 18–79 years). There was no
significant difference between the test and control groups with
respect to sex or age.
All subjects included in the study were informed of the nature of
the project, and informed verbal consent was obtained before their
participation in the study, which was recorded by the physician
who explained the study procedure. Written informed consent was
not used because of the nature of the study design, which utilized
serum samples taken after routine tests. The study protocol and
the form of consent were approved by the Ethics Committee of
National Center for Clinical Laboratories.
Bispecific antibody ELISA
Rabbit IgG (Sigma-Aldrich, St. Louis, MO, USA) was labeled
with horseradish peroxidase (HRP; Sigma-Aldrich, St. Louis, MO,
USA), using the periodate oxidation method as described
previously [14]. IgG-HRP conjugates were separated on a
SephacrylTM S-200 column (1.0640 cm; Pharmacia, Uppsala,
Sweden). Optimal work concentration for the conjugates was
determined by chessboard titrations by using an RF-positive serum
pool.
A sandwich ELISA was established with CCP-coated ELISA
plates (Immunoscan CCPlus; Euro-Diagnostica, Malmo, Sweden)
to detect bispecific antibodies originating from anti-CCP and RF.
Before the test, sera were treated with concanavalin to eliminate
interference from IgM RF [15]. For the assay, 100 mL serum
samples diluted 1:50 in phosphate-buffered saline (PBS)–1% (m/v)
gelatin (G9382; Sigma-Aldrich, St. Louis, MO, USA) was added in
duplicate to plate wells. The plates were subsequently incubated
for 1 h at room temperature (25uC), followed by 3 washes with
PBS–0.05% Tween 20 (PBST). Rabbit IgG-HRP conjugate
(100 mL) diluted 1:400 in PBST-1% gelatin was added to each
test well. After 1 h incubation at room temperature, the plates
were washed 5 times with PBST. After the addition of 100 mL/
well tetramethyl benzidine (T0440; Sigma-Aldrich, St. Louis, MO,
USA), the plates were incubated for 30 min at room temperature
for color development. The reaction was stopped by the addition
of 50 mL of 0.5 M sulfuric acid. Optical densities (O.D.) were read
at 450 nm with wavelength correction at 620 nm (OD450/
620 nm) in a plate reader (Labsystems, Finland).
IgG anti-CCP and IgG RF detection
Serum antibodies directed to cyclic citrullinated peptide (anti-
CCP) were assessed by a commercial ELISA kit (Immunoscan
CCPlus; Euro-Diagnostica, Malmo, Sweden) according to the
manufacturer’s recommendations. All sera were tested in dupli-
cate, and the results (OD450/620 nm) were averaged.
IgG RF was detected as described previously with some
modifications [15–16]. Before the assay, sera were treated with
concanavalin to eliminate interference from IgM RF [15]. In brief,
microtiter plates (Nunc Maxisorp, Roskilde, Denmark) were
coated with 100 mL rabbit IgG (5 mg/mL) in carbonate buffer
(0.05 M, pH 9.6) at 4uC overnight. After wash steps, the wells
were blocked and 1:100 diluted serum was added (100 mL/well).
Wells without antigens were set up for each sample to determine
nonspecific binding. The plates were incubated at room
temperature for 1 h followed by 3 washes with PBST. HRP-
conjugated anti-human IgG (1:10,000 diluted; Sigma-Aldrich, St.
Louis, MO, USA) was applied (100 mL/well). The plates were left
at room temperature for 1 h. The wells were washed again, and
100 mL substrate solution was added. Color development was
stopped after 30 min, and the absorbance was read at 450 nm. All
samples were tested in duplicate, and the results were averaged. A
positive serum pool was included in each assay to correct
interassay variations. The net absorbance for each sample was
obtained by subtracting the nonspecific binding derived from the
wells without rabbit IgG.
IgG4 subclass detection
IgG4 anti-CCP were detected by substituting the anti-human
IgG enzyme conjugate of the commercial anti-CCP assay with
HRP-conjugated mouse monoclonal antibody against human
IgG4 (HP6025; GeneTex, Irvine, CA, USA) diluted 1:25,600 in
PBST-1% gelatin.
For the IgG4 RF assay, EIA microplate wells (Costar) were
coated overnight at 4uC with 100 mL rabbit IgG at a concentra-
tion of 5 mg/mL in 50 mM sodium carbonate buffer (pH 9.6).
The plates were then washed 3 times with PBST and blocked with
200 mL/well PBS–1% gelatin for 1 h at 37uC. After washing,
100 mL of each serum previously treated with concanavalin and
diluted 1:50 in blocking buffer was applied to each well. The plates
were incubated for 1 h at room temperature. After washing,
100 mL/well HRP-conjugate IgG4-specific mouse monoclonal
antibody against human IgG4 diluted 1:10,000 in PBST–1%
gelatin was applied, and the plates were incubated at room
temperature for 1 h. The plates were then washed 5 times, and
color was developed as described above. All samples were tested in
duplicate, and the results were averaged.
Mixing test
To validate the bispecificity, anti-CCP and RF were mixed in
vitro and the bispecificity and anti-CCP levels were determined.
In a preliminary study, 2 serum samples were selected to
conduct the mixing test. Serum #32 was obtained from the RA
group, which presented predominantly anti-CCP compared to RF
or bispecific antibodies. Serum #3 was obtained from a patient
with pSS who possessed a high RF level as well as negative anti-
CCP and bispecific antibodies. A healthy serum that was negative
in all antibody assays was used as a control.
Bispecific Antibodies in Rheumatoid Arthritis
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of serial diluted serum #3 (1:25, 1:50, 1:100, 1:200, 1:400, or
1:800) or 1:25 diluted control serum. Each mixed serum (100 mL)
was blended thoroughly and added to 4 CCP-coated microwells in
parallel: 2 wells for the bispecific antibody assay and 2 for the IgG
anti-CCP assay as described above.
Based on the preliminary assay, we expanded our studies to
another 3 anti-CCP-positive but bispecific antibody-negative
serum samples (#9, #30, and #40; diluted 1:25 for the test)
and 5 RF predominant serum samples (#6, #33, #53, #58, and
#61; diluted 1:25 for the test). Data regarding anti-CCP, RF, and
bispecific antibodies for the samples included in the mixing tests
are shown in Table 1.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 for Windows.
Antibody levels between different groups were compared by the
nonparametric Mann–Whitney U-test.Spearman’srank correlation
was used to assess the relationship of bispecific antibodies with IgG
anti-CCP, IgG RF, IgG4 anti-CCP, and IgG4 RF. Two-sided p-
values less than 0.05 were considered statistically significant.
Results
Bispecific antibody detection in study populations
Patients with RA had higher optical densities (OD450/620 nm)
of bispecific antibodies (median OD: 0.096, interquartile range:
0.947) than healthy controls (median OD: 0.030, interquartile
range: 0.005) and patients with other autoimmune diseases (median
OD: 0.022, interquartile range: 0.012) (p,0.001 for both) (Fig. 1).
Correlations of bispecific antibodies with IgG anti-CCP,
IgG RF, IgG4 anti-CCP, and IgG4 RF
The profiles of RF, anti-CCP, and bispecific antibodies for 66
RA patients are shown in Figure 2. The bispecific antibodies were
strongly correlated with IgG RF (r=0.792, p,0.001) and were
reasonably correlated with IgG4 anti-CCP (r=0.507, p,0.001);
however, relatively weak correlations were found with IgG anti-
CCP and IgG4 RF (r=0.401, p=0.001 and r=0.249, p=0.044,
respectively) (Fig. 3).
Mixing test
Mixtures of sera #32 and #3 gave positive results in the
bispecific antibody assay, which became weaker with increasing
dilutions of #3 (Fig. 4A). As a control, serum #32 was mixed with
normal serum and the resultant bispecific signal was extremely low
(mean OD: 0.045, data not shown). In parallel, anti-CCP was
assessed in mixtures of #32 and #3; the results were nearly the
same as those of #32 mixed with normal serum. Likewise, another
3 anti-CCP-positive but bispecific antibody–negative samples were
mixed with 5 RF predominant samples pairwise; the bispecific
antibody and anti-CCP assays were performed for each pair. The
results varied greatly among samples (Fig. 4B). Bispecific
antibodies were detected in serum #9 after it was mixed with
any of the 5 RF-containing samples; meanwhile, #30 and #40
could only create evident bispecific signals when mixed with #61.
Likewise, the anti-CCP results were also the same compared to
those before mixing, independent of the bispecific results (Fig. 4C).
Table 1. Data of anti-CCP, RF, and BsAb for samples included
in mixing tests.
Serum
No.
Anti-CCP
(OD450)
RF
(OD450)
BsAb
(OD450)
#32 1.300 0.332 0.084
#3 0.075 3.522 0.026
#9 1.215 0.956 0.023
#30 0.556 0.912 0.062
#40 0.947 0.999 0.049
#6 0.067 2.532 0.035
#33 0.085 2.397 0.057
#53 0.055 2.977 0.048
#58 0.069 2.846 0.052
#61 0.061 3.363 0.039
OD450: optical densities at 450 nm with wavelength correction at 620 nm; Anti-
CCP: antibodies against cyclic citrullinated peptide; RF: rheumatoid factor; BsAb:
bispecific antibodies.
doi:10.1371/journal.pone.0016527.t001
Figure 1. Bispecific antibody results in RA patients and
controls. Serum samples from 66 patients with rheumatoid arthritis
(RA), 62 patients with other autoimmune diseases (Non-RA), and 50
healthy controls (HC) were analyzed by bispecific antibody ELISA.
Results were averaged and are expressed as optical densities at 450 nm
(OD450/620 nm).
doi:10.1371/journal.pone.0016527.g001
Figure 2. Bispecific antibodies (BsAb), IgG anti-CCP, and IgG RF
detection results for 66 RA patients. Numbers along the x-axis are
serum numbers. Bars represent the sum of optical densities at 450 nm
(OD450/620 nm) for BsAb, IgG anti-CCP, and IgG RF.
doi:10.1371/journal.pone.0016527.g002
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In the present study, we report a type of naturally occurring
bispecific antibody originating from anti-CCP and RF in RA
patients.
The situation described here might be confusing as RF is
involved. RF is a common autoantibody directed against the Fc
portion of IgG that is either in a complex with its respective
antigens or in an aggregated form. RF is an expression product of
an individual’s immune response to the presence of an aberrant
immunoglobulin molecule that is recognized by the body as
‘‘nonself.’’ The majority of RF belongs to the IgM immunoglob-
ulin class, while fewer belong to the IgG and IgA classes [17]. It is
widely believed that RF can cause a high level of false positives in
indirect ELISA, especially for the detection of IgM antibodies
[18]. Thus, it is possible that RF binds to the plate where IgG anti-
CCP is captured; thus, what appears to be bispecificity is merely
the formation of immune complexes on the plate. To exclude this,
1 anti-CCP-positive but bispecific antibody–negative serum (#32)
was mixed with a RF predominant serum (#3) to imitate the status
of samples where anti-CCP and RF coexist. If the apparent
bispecificity were the results of an artifact due to the formation of a
complex of RF with the captured IgG anti-CCP, the RF present in
the mix would be expected to interfere with the detection of anti-
CCP, thus producing inaccurate results. However, we did not
observe any obvious changes when anti-CCP was mixed with
different titers of RF (Fig. 4A). This is in agreement with rare
reports on the RF interference in anti-CCP tests. Meanwhile, the
undisturbed results for anti-CCP after the addition of RF also rule
out another potential source of artifacts in the measurement of
bispecific antibodies in which RF is complexed with captured anti-
CCP via Fc interactions [19]. On the other hand, the fact that not
all samples containing higher levels of RF and anti-CCP produce
higher bispecific signals also contradicts the artificial suspicion of
bispecificity (Fig. 2). Besides, bispecific antibodies could not be
detected when mixing #3 with a hepatitis C virus (HCV)
antibody–containing serum that was incubated with HCV
antigen–coated microwells and subsequently detected by rabbit
IgG-HRP (data not shown). Thus, the production of bispecific
antibodies is specific between anti-CCP and RF.
Recently, we published a paper describing the establishment of
an animal model for the production of natural bispecific antibodies
in rabbits. From our results, we draw a conclusion that natural
bispecific antibodies are readily produced if a body receives
simultaneous stimulation by 2 distinct antigens [1]. We believe this
is a general rule for bispecific antibodies that occur naturally in
vivo. In humans, a class of natural bispecific antibodies can be
obtained from allergic patients receiving therapeutic injections
with 2 different allergens during specific immunotherapy, which is
in agreement with the results described in our animal models [2].
For RA, the body responds to a variety of autoantigens in
conjunction with the development of the disease. This is similar to
that described in the animal models, but substituting exogenous
antigens with autoantigens. Since RF and anti-CCP are 2
common autoantibodies in RA, there is an increased possibility
Figure 3. Correlations between bispecific antibodies (BsAb) and various IgGs in RA patients. For the 66 RA patients, BsAb, IgG anti-CCP,
IgG RF, IgG4 anti-CCP, and IgG4 RF were determined by ELISA in duplicate. The mean optical densities at 450 nm with wavelength correction at
620 nm (OD450/620 nm) were obtained. The relationship of BsAb with IgG anti-CCP (A), IgG RF (B), IgG4 anti-CCP (C), and IgG4 RF (D) were assessed
by Spearman’s rank correlation coefficient. Two-sided p-values less than 0.05 were considered statistically significant.
doi:10.1371/journal.pone.0016527.g003
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together. In humans, natural bispecific antibodies are believed to
be relevant to the IgG4 subclass, and half-molecule exchanges
between 2 IgG4 molecules with distinct specificities are used to
explain such natural bispecificity [5]. Although the correlation was
not as strong as with IgG RF, the presence of bispecific antibodies
in our samples correlated positively with the presence of IgG4 anti-
CCP and IgG4 RF (r=0.507, p,0.001, and r=0.249, p=0.044,
respectively), suggesting that the IgG4 subclass may play a role in
the formation of natural bispecific antibodies against CCP and
rabbit IgG in RA patients. Previous studies on the subclass
distribution of anti-CCP and RF in RA indicate that IgG4 is
conspicuously elevated, only secondarily to IgG1; this further
confirms the conclusion mentioned above [10-12]. Because
autoimmune responses arise spontaneously and involve complex
phenomena, the occurrence of bispecific antibodies in RA
described here can not be simply described by the models of
immunotherapy with allergens, in which bispecificity is believed to
be solely a function of the IgG4 subclass [2]; other factors related
to the disease may play a role.
In our animal model, it is mentioned that the serum
environment is critical for conducting half-molecule exchanges
in vivo; however, in vitro, some reductive agents such as
glutathione (GSH) must be added to facilitate the exchanges [1].
Schuurman et al. [2] demonstrate an in vitro test using 2 IgG4
monoclonal antibodies in the presence of 0.5 mM GSH; we
reproduced this using 2 purified monospecific antibodies in the
same manner as described in our previous report [1]. However,
bispecific antibodies can also be produced in vitro when mixing 2
specific sera in diluent without adding any reductive reagents as
described in our mixing tests. A reasonable explanation for this is
that the diluted serum matrix may work as accelerators for the
production of bispecific antibodies. IgG4 is characterized by the
instability of the hinge domains, which is reflected by equilibrium
between inter- and intraheavy chain disulfide bonds [20]. Thus, a
redox-coupled process might facilitate the half-molecule exchange
reaction. It is indicated that the activation, proliferation, and death
of cells (apoptosis) are under the control of oxidative balance and
are key players in autoimmune pathogenesis and progression [21].
The hallmarks of RA are leukocytic infiltration and activation,
synovial proliferation, apoptosis, and the production of a series of
autoantibodies. These physiopathological events may in turn affect
the redox state of the internal environment. Consequently, we
postulate that environmental factors that favor the assembly of
bispecific antibodies, such as the oxydo-reductive potentials of the
internal environment, might account for the production of
bispecific antibodies in our mixing tests. This also appears to be
the explanation for the diversity of the bispecificity among
different serum pairs in mixing tests. Nevertheless, this speculation
needs to be carefully checked out by future research.
The bispecific antibodies that occur naturally in vivo may play a
special role in the immune responses associated with human diseases.
Natural bispecific antibodies are functionally monovalent and
therefore cannot crosslink antigens and trigger pathophysiological
effects associated with antigen aggregation. Besides, these antibodies,
whichareoftenoftheIgG4type,areunlikelytoburdeninflammation
but rather ease the situation because of their inability to activate
complement. Furthermore, the anti-inflammatory activity of bispe-
cific antibodies,which originates from the half-moleculeexchanges of
2 IgG4 molecules, was confirmed in vivo in a rhesus monkey model
with experimental autoimmune myasthenia gravis [5]. Considering
these aspects, we postulate that the production of natural bispecific
antibodies originating from anti-CCP and RF may be a beneficial
event for RA patients since these antibodies have the potential to
serve as indicators for disease remission.
In summary, we identified a type of antibody in RA that
exhibits bispecificity against CCP and rabbit IgG. The presence of
Figure 4. Bispecific antibodies (BsAb) and anti-CCP assay in
mixing tests. (A) One anti-CCP-positive but BsAb-negative serum (#32)
was mixed with different dilutions of one RF predominant serum (#3);
concentrations of BsAb and anti-CCP in the mixtures were determined.
Results are expressed as mean optical densities at 450 nm with wavelength
correction at 620 nm (OD450/620 nm). Dilutions of #3 are marked on the x-
axis. The dashed line indicates the anti-CCP results produced by mixing #32
with normal serum. For (B) and (C), another 3 anti-CCP-positive but BsAb-
negative sera (#9, #30, and #40; diluted 1:25 for the tests) were mixed with
5 RF-containing sera (#6, #33, #53, #58, and #61; diluted 1:25 for the
tests) pairwise; BsAb and anti-CCP were detected before and after mixing.
The 3 anti-CCP-positive sera are marked on the x-axis. (B) BsAb results before
and after mixing. Bars represent mean optical densities in BsAb detection
after mixing. The dashed line indicates the mean OD450/620 nm of BsAb for
sera #9, #30, and #40 before mixing. (C) Anti-CCP results before and after
mixing. Bars represent mean OD450/620 nm in anti-CCP detection after
mixing. The dashed lines indicate the OD450/620 nm of anti-CCP for sera
#9, #30, and #40 before mixing, respectively.
doi:10.1371/journal.pone.0016527.g004
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environmental factors, collectively influence the generation of
bispecific antibodies. The natural bispecific antibodies involved in
human diseases may have particular significance in the under-
standing of these diseases from a new perspective. Since natural
bispecific antibodies are thought to have anti-inflammatory
activities, it would be intriguing to further investigate the clinical
relevance of bispecific antibodies for RA patients with respect to
disease progression and prognosis, as well as explore other
autoimmune disease-associated bispecific antibodies.
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